SCHEMBL13086759

SCHEMBL13086759

CCOC(C)Oc1ccccc1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.41
TSHR P16473 4/20 0.41
CYP3A4 P08684 3/20 0.41
CYP2D6 P10635 3/20 0.41
SLC6A2 P23975 3/20 0.41
CHRM1 P11229 2/20 0.41
ADRA2B P18089 2/20 0.41
HTR2A P28223 2/20 0.41
HTR2C P28335 2/20 0.41
SLC6A4 P31645 2/20 0.41
HRH1 P35367 2/20 0.41
OPRM1 P35372 2/20 0.41
DRD3 P35462 2/20 0.41
OPRK1 P41145 2/20 0.41
HTR2B P41595 2/20 0.41
SLC6A3 Q01959 2/20 0.41
KCNH2 Q12809 2/20 0.41
KLF10 Q13118 2/20 0.41
HRH3 Q9Y5N1 2/20 0.41
LMNA P02545 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23906795 0.88 LMNA (0.48) ADRA2BLMNAKMT2ATDP1KDM4E
SCHEMBL1592873 0.83 NISCH (0.47) CYP1A2TSHRCYP3A4CYP2D6SLC6A2
O-Xylene SCHEMBL28066372 0.81 LMNA (0.57) CYP1A2TSHRCYP3A4CYP2D6HTR2A
SCHEMBL27701197 0.81 CA1 (0.50) CYP1A2TSHRCYP3A4CYP2D6SLC6A2
SCHEMBL8218163 0.81 ADRA2A (0.48) CYP1A2CYP3A4CYP2D6SLC6A2CHRM1
SCHEMBL27603149 0.80 LMNA (0.33) CYP1A2TSHRCYP3A4CYP2D6HTR2A
SCHEMBL1289387 0.79 NISCH (0.45) CYP1A2TSHRCYP3A4CYP2D6SLC6A2
SCHEMBL11586213 0.79 NISCH (0.45) CYP1A2TSHRCYP3A4CYP2D6SLC6A2
SCHEMBL11554545 0.79 TSHR (0.45) TSHRCYP3A4LMNATP53ALOX15
SCHEMBL4201350 0.79 LMNA (0.39) ADRA2BLMNAKMT2AKDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10289001-B2 Pattern forming method, etching method and method for producing capacitance-type input device FUJIFILM CORPORATION (JP) 2019-05-14 US disclosed
US-9810984-B2 Photosensitive transfer material, pattern formation method, and etching method FUJIFILM CORPORATION (JP) 2017-11-07 US disclosed
US-9810984-B2 Photosensitive transfer material, pattern formation method, and etching method FUJIFILM CORPORATION (JP) 2017-11-07 US disclosed
US-20170199458-A1 PATTERN FORMING METHOD, ETCHING METHOD AND METHOD FOR PRODUCING CAPACITANCE-TYPE INPUT DEVICE FUJIFILM CORPORATION (JP) 2017-07-13 US disclosed
US-20170199458-A1 PATTERN FORMING METHOD, ETCHING METHOD AND METHOD FOR PRODUCING CAPACITANCE-TYPE INPUT DEVICE FUJIFILM CORPORATION (JP) 2017-07-13 US disclosed
US-20160291468-A1 PHOTOSENSITIVE TRANSFER MATERIAL, PATTERN FORMATION METHOD, AND ETCHING METHOD FUJIFILM CORPORATION (JP) 2016-10-06 US disclosed
US-20150219993-A1 PHOTOSENSITIVE TRANSFER MATERIAL, PATTERN FORMATION METHOD, AND ETCHING METHOD FUJIFILM CORPORATION (JP) 2015-08-06 US disclosed
US-20100261758-A1 HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS NOVARTIS AG (CH) 2010-10-14 US disclosed
US-20100261758-A1 HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS NOVARTIS AG (CH) 2010-10-14 US disclosed
WO-2007110237-A2 AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREATMENT OF G PROTEIN RELATED DISEASES NOVARTIS AG (CH) 2007-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261758-A1 HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS HRH4, CNR1, CNR2 CYP1A2 19/4885TSHR 384/4885CYP3A4 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.